SRPT earnings date and last-quarter result: last quarter miss, P/E 25.52. Updated 2026-07-23.
Sarepta Therapeutics (SRPT) Research Hub
Sarepta Therapeutics (SRPT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 17.98 USD (+1.41%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 25.52, market cap 1.68B. This hub links to the full technical, earnings and options research available for SRPT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 17.98 USD (+1.41%) |
| 52-week range | 14.84 USD – 23.34 USD |
| Trend regime | Range |
| 14-day RSI | 54 (Neutral) |
| Trailing P/E | 25.52 |
| Market cap | 1.68B |
| Dividend yield | 0.00% |
Available research for SRPT
Covered Call on SRPT: how it works, illustrative setup around the real 17.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SRPT: how it works, illustrative setup around the real 17.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SRPT: how it works, illustrative setup around the real 17.98 USD price, max profit/loss, breakeven and when to use it. Educational.
SRPT technical analysis: range, last 17.98 USD, RSI 54, 52w range 14.84 USD–23.34 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SRPT in?
Sarepta Therapeutics (SRPT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SRPT in an uptrend or downtrend?
As of 2026-10-26, SRPT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SRPT's trailing P/E ratio?
SRPT's trailing P/E is 25.52, with a market cap of 1.68B. See the earnings research page for full valuation detail.